Based on these results, Albireo expects to recruit 180 patients with persistent idiopathic constipation in a US phase 2b study ( under an IND recently placed into impact by the FDA.. Albireo completes A3309 phase 1b study in patients with chronic idiopathic constipation Albireo today announced the completion of a phase 1b study showing a favorable tolerability and safety profile of A3309 in patients with chronic idiopathic constipation. In addition, the info revealed appropriate efficacy indicators in this patient populace.All groups were comparable in term of mean gender and age distribution. In addition, there were no significant distinctions between the BD alone and BD+ADHD organizations regarding mood symptom severity, and no significant difference between the ADHD only and BD+ADHD groupings regarding ADHD symptom severity. All of the participants underwent useful magnetic resonance imaging of the mind while performing a response inhibition job . Analysis of the findings revealed that sufferers in the BD+ADHD group had significantly higher activation in the anterior cingulate , the posterior cingulate, and bilateral thalamus than people that have BD alone. BD+ADHD individuals also showed significantly higher activation than people that have BD alone in the remaining inferior frontal cortex , the right excellent frontal gyrus , the right parahippocampal, and still left supramarginal gyrus.